Allergen-induced airway inflammation and Th2 cell development requires Blimp-1

Kun He[1,2,5], Angela Hettinga[1,2,5], Sagar Kale[2,3], Markus M. Xie[4], Alexander L. Dent[4],

Anuradha Ray[2,3] and Amanda C. Poholek[1,2] *

[1]Division of Pediatric Rheumatology, Department of Pediatrics, University of Pittsburgh

School of Medicine, Pittsburgh, PA 15261, USA.

[2]Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA

15213, USA.

[3]Department of Pulmonary, Allergy, and Critical Care Medicine, Department of

Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh,

Pittsburgh PA, 15213, USA.

[4]Department of Microbiology and Immunology, Indiana University School of Medicine,

Indianapolis, IN, 46202 USA.

[5]These authors contributed equally: Kun He, Angela Hettinga

*Correspondence: poholeka@pitt.edu

Summary: The transcriptional repressor Blimp-1 acts via a pro-inflammatory IL-10-

STAT3 axis as a critical positive regulator of Th2 cells in the lung in response to

allergens driving pathophysiology associated with asthma disease.

Abstract

A Th2 immune response is central to allergic airway inflammation, which afflicts millions

worldwide. However, the mechanisms that augment GATA3 expression in an antigen-

primed developing Th2 cell are not well understood. Here, we describe an unexpected

role for Blimp-1, a transcriptional repressor that constrains autoimmunity, as an

upstream promoter of GATA3 expression that is critical for Th2 cell development in the

lung, but dispensable for T_{FH} function and IgE production. Mechanistically, Blimp-1

intrinsically represses Bcl6, which is necessary to drive GATA3 expression.

Surprisingly, the anti-inflammatory cytokine IL-10, but not the pro-inflammatory

cytokines IL-6 or IL-21, is required via STAT3 activation to upregulate Blimp-1 and

promote Th2 cell development. These data reveal a hitherto unappreciated role for an

IL-10-STAT3-Blimp-1 circuit as an initiator of an inflammatory Th2 response in the lung

to allergens. Thus, Blimp-1 in a context-dependent fashion can drive inflammation by

promoting rather than terminating effector T cell responses.

Introduction

Asthma is a complex, chronic inflammatory disease of the airways. House dust mite

(HDM) is a major indoor allergen that is globally ubiquitous in living environments and is

capable of inducing allergic lung inflammatory diseases (Calderón et al., 2015). Immune

cell infiltration, including eosinophils and IgE-mediated sensitization are hallmarks of

allergic airway disease, which is primarily driven by strong type2 cytokine responses

(such as IL-4, IL-5 and IL-13) predominantly produced by activated $CD4^+$ T cells of a

Th2 phenotype(Lambrecht and Hammad, 2015; Licona-Limón et al., 2013; Pascual and

Peters, 2005; Ray and Cohn, 1999; Zhang et al., 1999). Th2 cells are differentiated

following the activation of naive $CD4^+$ T cells in the presence of IL-4, and the master

transcription factor GATA3(Kopf et al., 1993; Zhang et al., 1997; Zheng and Flavell,

1997). However, the signals that support this process in vivo are still not well

understood (Lambrecht and Hammad, 2015; Pulendran et al., 2010). Several IL-4

secreting cells have been proposed to promote Th2 cell development such as NKT

cells, basophils, or early-activated CD4 T cells(Croft and Swain, 1995; Seder et al.,

1991; Yoshimoto et al., 1995). However, there is evidence that IL-4-independent Th2

cell differentiation can occur, suggesting additional cytokines may play an important role

in initiating or supporting Th2 cell differentiation in response to allergens (Dent et al.,

1998; Oliphant et al., 2011; Ouyang et al., 2000; Stritesky et al., 2011). As evidence,

both STAT3 signaling and cytokines such as thymic stromal lymphopoietin (TSLP) can

promote Th2 cell differentiation (Rochman et al., 2018; Stritesky et al., 2011). Thus,

additional regulators of Th2 cells beyond the IL-4-STAT6-GATA3 circuit play a role in

type2 immune responses.

B lymphocyte-induced maturation protein-1 (Blimp-1) is a transcriptional repressor

required for plasma cell development and function (Minnich et al., 2016; Turner et al.,

1994). However, Blimp-1 also has important functions in T cells to regulate effector

responses (Crotty et al., 2010; Fu et al., 2017). Conditional deletion of Blimp-1 in T cells

causes spontaneous accumulation of effector T cells and systemic autoimmunity,

suggesting that Blimp-1 constrains T cell-mediated autoimmunity (Kallies et al., 2006;

Martins et al., 2006). In CD4 T cells, Blimp-1 can repress Bcl6 to antagonize T follicular

helper cell (T$_{FH}$) differentiation, control IL-10 expression in effector (Th1 and Th17) and

regulatory T cells (Tregs), and regulate the differentiation and function of effector T cells

(Cretney et al., 2011; Johnston et al., 2009; Neumann et al., 2014; Parish et al., 2014).

Furthermore, we previously found that overexpression of Blimp-1 could lead to cell

death, suggesting Blimp-1 also controls effector responses by limiting effector cell

numbers directly (Poholek et al., 2016).

Our previous studies showed that disrupting Blimp-1 in T cells increased Th2 responses

in a worm antigen model. Therefore, we hypothesized that T cell specific deficiency of

Blimp-1 in an allergic airway inflammation model would lead to increased expansion of

effector cells and more severe disease due to increased Th2 responses. Unexpectedly,

we found that T cell specific Blimp-1 deficiency protected mice from the development of

allergic lung inflammation and Th2 cells in the lung were severely reduced. STAT3 via

IL-10 was required for Blimp-1 expression and Th2 cell development in this model,

suggesting IL-10 may play an unexpected role in supporting Th2 cell differentiation.

Mechanistically, our data supports an intrinsic role for Blimp-1 mediated repression of

Bcl6, which in turn can repress GATA3. Thus, Blimp-1 indirectly supports Th2

differentiation by promoting GATA3 expression. These data identify a new context-

dependent role for Blimp-1 in T cells that is essential for the full development of allergic

lung disease, highlighting a previously unappreciated pathway with potential therapeutic

targets for the treatment of asthma disease.

Results

Blimp-1 in T cells promotes allergic airway inflammation

Blimp-1 controls effector T cell responses and constrains autoimmunity(Crotty et al.,

2010; Poholek et al., 2016). We reasoned that during a house dust mite (HDM) induced

model of allergic lung disease, the absence of Blimp-1 in T cells would drive increased

effector T cells and exacerbate disease. To test this, we compared mice in which Blimp-

1 was conditionally deleted in all T cells (Blimp-1$^{f/f}$ x CD4-cre, referred to as Blimp-

1^{CD4Cre}) to Cre-negative littermate controls (Blimp-1$^{f/f}$). Allergic inflammation in the

airways was induced by repeated intranasal (i.n.) administration of HDM antigen for 10

days (priming) followed by two re-challenges of 2-3 days each after rests of 3-4 days

(Fig S1A). As expected, histological assessment of lung tissue following HDM

administration of control animals revealed substantial lymphocyte infiltration to the

tissue and mucus in the airways, indicating a robust allergic inflammatory response to

HDM had occurred (Fig 1A). In addition, neutrophils, eosinophils, lymphocytes and

monocytes were readily found in the bronchiolar lavage fluid (BAL) of control animals

(Fig 1B). Contrary to our hypothesis, we found that Blimp-1^{CD4Cre} animals had no signs

of inflammation based on histological analysis of lung tissue (Fig 1A). Analysis of BAL

identified a specific loss of eosinophils, suggesting type2 immunity was impaired (Fig

1B). Eosinophils are recruited by Th2 cells that produce IL-5, while mucus in the

airways is due to the presence of IL-13$^+$ cells (Erle and Sheppard, 2014; McBrien and

Menzies-Gow, 2017). To determine if there were alterations in the CD4$^+$ T cell response

to HDM, we isolated lymphocytes from the lung and mediastinal lymph node (mLN) and

assessed CD4 T cell subsets by flow cytometry. HDM is known to induce a mixed

response with differentiation/expansion of Th1, Th2 and Th17 cells. We observed robust

increases of Th1, Th2 and Th17 cells as well as T regulatory cells (Treg) in the lungs of

control animals compared to unimmunized, naïve animals (Fig 1C, D). In contrast,

Blimp-1^{CD4Cre} animals were specifically lacking Th2 cells (GATA3$^+$ IL-13$^+$ or GATA3$^+$ IL-

5$^+$) in the lung, while Th1 and Th17 cells were largely unaffected (Fig 1C,D). These

results were surprising as prior examination of Blimp-1 in T cells has resulted in

increased Th2 effector T cell responses in a Th2 model (Poholek et al., 2016)and in

vitro, Blimp-1 is not required for Th2 cell differentiation (Fig S1B)(Cimmino et al., 2008).

In contrast to the lungs, Blimp-1^{CD4Cre} mice had increased Th1 and Th17 cells in the

mLN, but Th2 cells (GATA3$^+$ IL-13$^+$) were largely absent, constituting less than 1% of all

CD4$^+$ T cells (Fig S1C)(Bao and Reinhardt, 2015). Consistent with previous

publications, Tregs were increased in Blimp-1^{CD4Cre} mice, likely due to Blimp-1's role in

repressing IL-2, and Tregs capability to expand in conditions with excess IL-2 (Fig

1C,D)(Cretney et al., 2011; D'Cruz and Klein, 2005; Fontenot et al., 2005; Malek et al.,

2002; Martins et al., 2008; Webster et al., 2009). Blimp-1 is well known to be a critical

driver of IL-10, and indeed Blimp-1^{CD4Cre} mice were specifically lacking IL-10 production

from T cells (Fig 1E,F, S1C)(Kallies et al., 2006; Martins et al., 2006; Neumann et al.,

2014; Parish et al., 2014). Bcl6 and Blimp-1 are transcriptional repressors known to

regulate one another in both T and B cells, thus we explored the levels of Bcl6 in CD4$^+$

T cells(Crotty et al., 2010). Blimp-1^{CD4Cre} mice had increased expression of Bcl6 in both

the lung and mLN (Fig 1E,F, S1C), suggesting that the absence of Blimp-1 in T cells

resulted in a concomitant increase in Bcl6. Together, these data suggest that Blimp-1

plays a surprising and critical role in driving the differentiation of Th2 cells in response to

inhaled allergens that is necessary for resulting inflammation in the lung tissue.

IgE responses are Blimp-1 independent

A hallmark of type2 driven allergic responses is the presence of high levels of circulating

IgE. In contrast to the decrease in type2 immunity observed in the lungs of Blimp-1^{CD4Cre}

animals (reduced Th2 cells and eosinophils in BAL), IgE levels were unchanged (Fig

2A). Isotype-switch to IgE is dependent on IL-4(Kopf et al., 1993). However, similar to

loss of Th2 cells in the lung, IL-4+ T cells in the mLN was significantly reduced in Blimp-

1^{CD4Cre} animals (Fig 2B,C). Antibody responses are largely driven by T follicular cells

(T$_{FH}$), and Blimp-1 antagonizes (T$_{FH}$) responses. Thus, we reasoned that T$_{FH}$ cell

responses would be intact in Blimp-1^{CD4Cre} and thus capable of driving robust IgE

responses. IL-4 can be produced by both Th2 and T$_{FH}$ cells(Zhu, 2015), therefore, we

determined the percentage IL-4$^+$ cells in both subsets (Th2, GATA3$^+$ and T$_{FH,}$ GATA3$^-$)

of cells in the mLNs of control and Blimp-1^{CD4Cre} animals. Despite total IL-4+ cells being

decreased in mLNs of Blimp-1^{CD4Cre} animals, analysis of IL-4+ cells within the T$_{FH}$

population (GATA3$^-$) was similar to controls (Fig 2D,E). In contrast, IL-4$^+$ cells within the

Th2 population (GATA3$^+$) were significantly reduced (Fig 2D,E). As expected,

expression of Bcl6 was higher in T$_{FH}$ cells (GATA3$^-$) than Th2 cells (GATA3$^+$) of control

animals, but still reduced compared to Blimp-1^{CD4Cre} animals (Fig S2A,B). Indeed, IL-4+

cells from control animals comprised both Th2 (GATA3+ IL-13+) and T$_{FH}$ (Bcl6+

CXCR5+) cells (Fig 2F). Blimp-1^{CD4Cre} animals, however, had similar IL-4+ T$_{FH}$ cell

percentages but Th2 cells were absent (Fig 2F). These data suggest that although

Blimp-1 is a master regulator of Th2 cell development in the lungs, it is not required for

IL-4$^+$ T$_{FH}$ cell development and subsequent type2 mediated IgE responses. Thus, there

are unique molecular pathways that can drive type2 humoral immunity for IgE

production (IL-4-producing T$_{FH}$ cells) distinct from those that drive eosinophil recruitment

to the lung (IL-13 and IL-5 producing Th2 cells), and Blimp-1 is a major regulator that

molecularly dissects these two independent pathways.

Blimp-1 is intrinsically required in T cells to promote Th2 cells

We next sought to determine if Blimp-1 was expressed by all CD4 T cell subsets in the

lung during the course of allergic airway inflammation, or if expression was limited to

Th2 cells. To assess Blimp-1 expression, we induced allergic inflammation in Blimp-1

yellow fluorescent protein (YFP) reporter mice, which reliably tracks Blimp-1

transcription by YFP (Rutishauser et al., 2009). We assessed each CD4 T cell subset

and Blimp-1 expression within each subset at 4 timepoints; day 6 and day 10 which are

during and after priming, day 18, after the first challenge and day 23 after the second

challenge. Th1, Th2, Th17 and Treg cells were present at each timepoint in the lung in

naïve unimmunized animals and after HDM challenges (Fig S3A). When looking at the

percentage of Blimp-1 YFP+ cells among each subset we found that all subsets initially

upregulated Blimp-1 but that Th2 cells did so to greater degree compared to Th1 and

Th17 cells. (Fig 3A-B, S3B). Tregs have been reported to express high levels of Blimp-1

in effector tissues, thus as a positive control we assessed Blimp-1 in Tregs and found

nearly all Tregs expressed Blimp-1 after HDM (Fig S3C)(Cretney et al., 2011). Blimp-1

continued to increase in Th2, Treg and Th17 populations, while the percentage of

Blimp-1+ cells in Th1 cells remained fairly constant over time after the initial increase

from day 0 to day 5 (Fig S3B).

It was possible that the increase in Tregs (Fig 1C,D) might be responsible for

suppressing Th2 cells. Therefore, we wondered if the expression of Blimp-1 was

required intrinsically in T cells to drive Th2 cells or if an extrinsic mechanism such as

Treg mediated control may be at play. To test the intrinsic function of Blimp-1, we

generated mixed bone marrow (BM) chimeras in Rag-deficient hosts where 50% of

donor BM was from congenically marked B6 Control mice (Thy1.1) and 50% from

Blimp-1^{CD4Cre} (Thy1.2). 6 weeks post reconstitution, allergic lung inflammation was

induced with HDM as previously described (Fig S3D). Although irradiated hosts

received equal percentages of donor BM, Blimp-1^{CD4Cre} BM reconstituted at greater than

50%, supporting its role in negatively regulating T cell survival (Poholek et al., 2016)

(Fig S3E). Nevertheless, Th2 cells were significantly reduced in Blimp-1^{CD4Cre} T cells

after HDM-induced allergic lung inflammation (Fig 3C,D). Tregs however were

equivalently derived from Control or Blimp-1^{CD4Cre} BM, suggesting that Blimp-1 is

intrinsically required in Th2 cells to promote Th2 cell differentiation and that increases in

Tregs was not responsible for this effect. The reduction in Th2 cells was significant

enough to result in a slight, but significant decrease in eosinophils in the BAL compared

to animals that only received control BM (Fig 3E). Blimp-1^{CD4Cre} T cells (Thy1.2+) had

significant decreases in IL-10 and increases in Bcl6 compared to control cells in the

same animal, consistent with Blimp-1's function in driving IL-10 and repressing Bcl6 (Fig

3C,D). Taken together these data suggest that the mechanism of Blimp-1 mediated Th2

cell differentiation is cell intrinsic.

STAT3 is required for Blimp-1 expression in T cells

We next explored the upstream drivers of Blimp-1 in Th2 cells in order to understand

how Blimp-1 might be controlling Th2 cell differentiation. Our previous examination of

Th2 cells found that STAT3, but not STAT6, was a critical regulator of Blimp-1(Poholek

et al., 2016).Furthermore, STAT3 can support Th2 cell differentiation in some contexts

(Stritesky et al., 2011). Therefore, we wondered whether STAT3 could be promoting

Th2 cell development through upregulation of Blimp-1. To explore the role of STAT3, we

used T cell specific STAT3 deficient animals (STAT3$^{f/f}$ CD4-Cre, referred to as

STAT3^{CD4Cre}) and assessed T cell subsets in the lung as well as the expression of

Blimp-1. After immunization with HDM, STAT3^{CD4Cre} lung tissue had reduced

lymphocytic infiltration as assessed by PAS staining and there was a significant

reduction in eosinophils found in the BAL (Fig 4A,B). Consistent with STAT3's role in

driving Th17 differentiation(Zhou et al., 2007), STAT3^{CD4Cre} had a complete absence of

Th17 cells in the lungs (Fig 4C). Intriguingly, we found a significant reduction in Th2

cells, similar to our results in Blimp-1^{CD4Cre}, confirming previous studies that STAT3

could support Th2 cell development in the context of allergic lung inflammation

(Stritesky et al., 2011) (Fig 4C). In contrast, Th1 cell percentages were similar in control

and STAT3^{CD4Cre} mice. To determine if STAT3 was required for Blimp-1 expression, we

assessed Blimp-1 protein expression in effector T cells. In agreement with our previous

study, Blimp-1 protein was significantly reduced in the absence of STAT3, suggesting

that STAT3 is required for Blimp-1 expression and subsequent Th2 differentiation in

allergic lung inflammation (Fig 4D). To confirm the loss of Blimp-1 in the absence of

STAT3, we crossed the STAT3^{CD4Cre} to Blimp-1 YFP reporter mice. Consistent with

STAT3^{CD4Cre} animals, Th2 cells were specifically reduced in STAT3^{CD4Cre} Blimp-1 YFP

after HDM (Fig 4E). STAT3^{CD4Cre} Blimp-1 YFP also had no Blimp-1 expression

(assessed by YFP) in Th1 or Th2 cells compared to control Blimp-1 YFP mice (Fig 4F).

Although Th1 cells also lacked Blimp-1, it did not affect Th1 cell percentages in the lung,

suggesting that Blimp-1 and STAT3 are not necessary for Th1 cell differentiation in

response to allergens. These data confirm the critical role of STAT3 in driving Blimp-1 in

Th2 cells in vivo in an allergic lung inflammation model. These data are in contrast to

our previously published work (Poholek et al., 2016) where Blimp-1 limits the

percentage of Th2 cells in a worm antigen model, suggesting there is a context-

dependent function for Blimp-1 in Th2 cells depending on the antigen or route of

immunization.

IL-6 and IL-21 are not required for expression of Blimp-1 in Th2 cells

We next sought to determine what environmental factors were driving Blimp-1

expression in Th2 cells in HDM induced lung inflammation. We focused our analysis on

known STAT3-activating cytokines. As IL-6 has previously been shown to support Th2

cells in allergic lung disease (Doganci et al., 2005) and is a strong STAT3 activator, we

first tested whether IL-6 signaling on T cells was required for Blimp-1 induction and Th2

cell formation in this model. Using IL-6Rα deficient T cells (IL-6R$\alpha^{f/f}$ CD4-Cre, referred

to as IL-6Rα^{CD4Cre}) we found no significant difference in Th2 cells in the lung after HDM,

however Th17 cells in the lung were absent, in line with the well-known role of IL-6 to

drive Th17 development via STAT3 (Fig 5A)**.** Importantly, Blimp-1 levels were

unchanged in effector (CD44$^+$) T cells (Fig 5B), suggesting IL-6 was not required to

drive Blimp-1 or Th2 cells in response to HDM.

To identify other possible STAT3-driven cytokines we performed whole-tissue qPCR of

both lung and mLN and found IL-10, IL-21, and IL-27 were all upregulated in response

to HDM, particularly in the mLN (Fig 5C). IL-21 is known to play a critical role in Th2 cell

generation in HDM induced allergic lung inflammation, however the mechanism is

unclear(Coquet et al., 2015). Furthermore IL-21 is known to drive Blimp-1 in B cells

(Ozaki et al., 2004). Using IL-21R deficient mice (IL-21R$^{-/-}$) we found a significant

reduction in eosinophils in the lung consistent with previous reports (Coquet et al.,

2015)(Fig 6A). We also found a significant reduction in Th2 cells in the lung and mLN

(Fig 6B, Fig S4A). Surprisingly, although IL-21R$^{-/-}$ displayed a loss of Th2 cells similar to

Blimp-1^{CD4Cre} and STAT3^{CD4Cre}, Blimp-1 levels were similar in effector T cells in both

control and IL-21R$^{-/-}$ animals (Fig 6C, Fig S4B). We wondered if IL-21 could play an

important role in driving Blimp-1 only in Th2 cells, and the absence of Th2 cells limited

our ability to detect this. To test this, we treated Blimp-1 YFP mice with anti-IL-21R

antibody (or control IgG antibody) during the course of HDM-induced allergic lung

inflammation and tracked Blimp-1 expression by YFP. Similar to IL-21R$^{-/-}$ mice, Th2

cells were significantly reduced in the lung of anti-IL-21R treated mice (Fig 6D).

However, Blimp-1 levels were intact in the few remaining Th2 cells found (Fig 6E).

While Blimp-1 levels were slightly reduced in Th1 cells, this had no effect on Th1 cell

development (Fig 6D-E). These data suggest that while IL-21 is critical for Th2 cell

development and eosinophil recruitment during HDM-induced allergic lung

inflammation, the role of IL-21 in Th2 cell formation is independent of the function of

Blimp-1 in driving Th2 cells.

IL-10 is required for Blimp-1 expression in Th2 cells

Our previous studies using worm-derived antigens (soluble egg antigens from *S.*

Mansoni) demonstrated that IL-10 is a critical factor driving Blimp-1 expression in Th2

cells(Poholek et al., 2016). Although IL-10 is thought to be anti-inflammatory in allergic

responses, we nonetheless explored if IL-10 might also be a driver of Blimp-1 in HDM-

induced allergic lung inflammation. To test this, we treated Blimp-1 YFP mice with anti-

IL10R antibody or IgG control during HDM immunization. Surprisingly, we found a

consistent reduction in eosinophils recruited to the lungs (Fig 7A), and a concomitant

decrease in Th2 cells in the lung (Fig 7B,C). Th1 cells were increased, while Th17 and

Treg cells were unaffected (Fig 7C, data not shown). Intriguingly, Blimp-1 was

specifically and significantly reduced in Th2 cells but unaffected in Th1 cells (Fig 7D,E),

suggesting IL-10 was an important regulator of Blimp-1 in Th2 cells in the context of

allergic antigen stimulation. As Blimp-1 is an intrinsic regulator of IL-10 expression (Fig

3D), we wondered if IL-10 expression was also affected by loss of Blimp-1. Within the

total effector (CD44$^+$) T cell population, IL-10 levels were unchanged (Fig S5A),

however in Th2 cells, expression of IL-10 shifted from a Blimp-1+ population in IgG

treated control mice, to a Blimp-1 negative population in anti-IL-10R treated mice (Fig

7F,G). These data suggest that Blimp-1 expression may not be continually required for

IL-10 expression in T cells. To address the possibility that IL-10 and IL-21 act in a

redundant fashion to regulate Blimp-1 expression we performed double antibody

blockade of both IL-10R and IL-21R in Blimp-1 YFP animals. Blockade of IL-10R and IL-

21R together did not have a synergistic effect on Blimp-1 expression, suggesting the

effects of IL-10 and IL-21 are independent of one another (Fig S5B,C). Taken together,

these data suggest that IL-10 is an important regulator of Blimp-1 in T cells supporting

Th2 cells in the lung during allergic inflammation. These data are somewhat counter-

intuitive as IL-10 is typically thought of as an anti-inflammatory cytokine and previous

studies implicated a role for IL-10 in suppressing Th2 cells (Coomes et al., 2016).

However, our data clearly point to an additional role of IL-10 in promoting inflammation

of the lung via Th2 cells and recruitment of eosinophils to the lung.

Blimp-1 supports GATA3 expression and Th2 development through suppression of Bcl6

We next sought to understand how Blimp-1 was functioning to control Th2 cell

differentiation. Since GATA3 is the master regulator of Th2 cell development (Zhang et

al., 1997; Zheng and Flavell, 1997), we determined more specifically the expression of

master regulators in T cell subsets in the absence of Blimp-1. Indeed, although T-bet

levels were unchanged, the loss of Blimp-1 led to a specific and robust decrease in

GATA3 (Fig 8A,B). Bcl6 is a well-known repressor of GATA3 (Kusam et al., 2003;

Sawant et al., 2012), and Blimp-1 deficient T cells had a robust increase in Bcl6

expression (Fig 1F). We hypothesized that in wildtype cells, Blimp-1 may be

suppressing Bcl6 to promote GATA3 expression, but that in Blimp-1^{CD4Cre} animals,

increased expression of Bcl6 would suppress GATA3 and Th2 cell development. To test

this, we induced allergic lung inflammation in mice that had a T cell specific deficiency in

both Blimp-1 and Bcl6 (Blimp-1$^{f/f}$ Bcl6$^{f/f}$ CD4Cre^{+}, referred to as doubleKO^{CD4Cre})(Xie et

al., 2017). Control (Bcl6$^{f/f}$ or Blimp-1$^{f/f}$, CD4Cre^{-}), Bcl6-deficient (Bcl6$^{f/f}$ CD4Cre^{+},

Bcl6^{CD4Cre}), Blimp-1^{CD4Cre} or doubleKO^{CD4Cre} mice were immunized with HDM and

assessed for lung inflammation as well as development of T cell subsets in the lung and

mLN. As before, examination of lung tissue found a consistent reduction in inflammation

in Blimp-1^{CD4Cre} lungs compared to Control or Bcl6^{CD4Cre} (Fig 9A). doubleKO^{CD4Cre} mice

had lymphocyte infiltration and mucus that was similar to controls, suggesting

inflammation was present when Bcl6 and Blimp-1 were both absent in T cells (Fig 9A).

Consistent with this finding, we saw no difference in the recruitment of eosinophils to the

BAL in the doubleKO^{CD4Cre} lungs compared to control or Bcl6^{CD4Cre}, however Blimp-

1^{CD4Cre} mice had a consistent reduction in eosinophils as seen previously (Fig 9B). In

the lung, Th1 cells were increased in both Blimp-1^{CD4Cre} and doubleKO^{CD4Cre} mice

compared to control and Bcl6^{CD4Cre} animals (Fig 9C). Interestingly, Th2 cells were

increased in doubleKO^{CD4Cre} compared to Blimp-1^{CD4Cre} mice, suggesting the loss of

Bcl6 in Blimp-1^{CD4Cre} was sufficient to restore Th2 cell differentiation (Fig 9C). Treg cells

in doubleKO^{CD4Cre} were increased compared to controls, similar to Blimp-1^{CD4Cre},

suggesting that Blimp-1's repression of IL-2 is Bcl6-independent (Fig 9C). As expected,

IgE levels were dramatically reduced in Bcl6^{CD4Cre} and doubleKO^{CD4Cre} mice, likely due

to the loss of T$_{FH}$ cells in the absence of Bcl6 expression (Fig 9D). Finally, we explored

the expression of IL-10 in both effector and Treg cells. Intriguingly, the absence of Bcl6

restored IL-10 expression in doubleKO^{CD4Cre}, suggesting the function of Blimp-1 in

driving IL-10 is via suppression of Bcl6 expression, and thus may be indirect rather than

direct, as previously reported (Fig 9E)(Minnich et al., 2016; Xie et al., 2017). This effect

was greater in Tregs than in effector T cells (Fig 9E). Taken together, these data

indicate that Blimp-1 functions intrinsically in T cells to suppress Bcl6 expression which

is permissive for GATA3 expression, subsequent development of Th2 cells, and

expression of IL-10 in T cells in the context of an HDM-induced allergic lung

inflammation model.

Discussion:

In this study, we have uncovered a previously unappreciated role for Blimp-1 in driving

Th2 cell development in the context of an allergen induced lung inflammation model.

House dust mite antigen is a widely used model of allergic lung inflammation owing to

its physiologic relevance to human health as dust mites are a well-known allergic trigger

in many individuals with asthma disease(Thomas, 2016). Based on our previous study,

we expected Blimp-1 to suppress inflammatory effector responses to HDM. On the

contrary, we uncovered an unexpected role for Blimp-1 in the specific control of Th2 cell

differentiation, which has not been previously demonstrated in *in vitro* assays or our

prior *in vivo* Th2 model (Cimmino et al., 2008; Poholek et al., 2016). Previous studies

exploring the role of Blimp-1 in T cells have elucidated many functions for Blimp-1 that

collectively could be described as controlling effector functions of T cells that mediate

disease states. In CD8 T cell responses to viral infection, Blimp-1 supports effector cell

differentiation while repressing memory cells (Kallies et al., 2009; Rutishauser et al.,

2009; Shin et al., 2009). Blimp-1 also plays a critical role in supporting IL-10 expression

in Tregs and effector CD4 T cells, the absence of which can have important

consequences for controlling infections by pathogens such as Toxoplasma or chronic

viral infection (Cretney et al., 2011; Neumann et al., 2014; Parish et al., 2014). Blimp-1

also controls differentiation of an inflammatory Th17 cell that produces IFNγ and GM-

CSF and subsequent autoimmune disease in an EAE model (Jain et al., 2016). In each

of these systems, Blimp-1 primarily controls effector properties of the T cells; supporting

cytokines such as IL-10, IFNγ, and GM-CSF, suggesting that Blimp-1 is part of a cell

program to further drive a terminal effector differentiation state. Finally Blimp-1 is known

to repress the differentiation of T$_{FH}$ cells(Johnston et al., 2009; Nurieva et al., 2009).

Here, for the first time, we have unexpectedly shown that Blimp-1 is essential for

supporting the differentiation of a lineage of helper cells, Th2 cells, suggesting Blimp-1

has a more complex role than previously appreciated.

Th2 cells are primary producers of several important type2 cytokines that drive

allergic lung disease, including IL-4, IL-5, and IL-13(Licona-Limón et al., 2013; Ray and

Cohn, 1999). Each of these cytokines has a unique function in asthma disease, but

collectively they enforce several hallmarks of asthma, including IgE production,

recruitment of eosinophils and mucus production in the airways. Intriguingly, we found

that Blimp-1 controlled only GATA3+ Th2 cells but was not required for all IL-4+

producing cells. T_{FH} cells are a critical population of effector T cells that is superior at

initiating and supporting B cell responses such as IgE(Crotty, 2011). Furthermore, they

can express IL-4, which is required for isotype switch to IgE(Zhu, 2015). Although the

loss of Blimp-1 did not result in an increase in T_{FH} cells after HDM, as it has in other

systems, IL-4$^+$ T_{FH} cells were intact, resulting in normal IgE responses to HDM despite

the absence of Th2 cells. These results suggest that the pathways that drive T_{FH} and

Th2 cells in response to allergens can be molecularly dissected, and that Blimp-1 is a

major regulator distinguishing these two inflammatory cell types. This may enable

therapeutic targeting of these populations distinctly, and supports further exploring the

upstream pathways of each cell population.

Multiple STATs including STAT3, STAT4 and STAT5 have been implicated in

driving Blimp-1 in effector T cells(Jain et al., 2016; Neumann et al., 2014; Xin et al.,

2016). In line with previous reports, we have found a central role for STAT3 in

upregulating expression of Blimp-1 (Jain et al., 2016; Poholek et al., 2016). Although we

had previously found that IL-10 was required for Blimp-1 expression in Th2 cells, we did

not initially explore IL-10 in this context for a few reasons. First, there are several well-

known STAT3 activating cytokines such as IL-6, IL-21, and IL-27, and several of these

had already been implicated in supporting Th2 cells in allergic lung disease

models(Coquet et al., 2015; Doganci et al., 2005; Leonard and O'Shea, 1998; Licona-

Limón et al., 2013; Rincon et al., 1997). Secondly, IL-10 generally is thought to act as

an anti-inflammatory cytokine and previous work had suggested IL-10 suppresses Th2

responses in an HDM driven model(Coomes et al., 2016; Tournoy et al., 2000).

However, we were surprised to find that neither IL-6 nor IL-21 signaling to T cells had

any significant function on Blimp-1 expression in T cells. Rather, IL-10 seems to play a

predominant role in regulating Blimp-1 in particular in Th2 cells. We initially

hypothesized that perhaps IL-21 initiated Blimp-1 expression while IL-10 maintained

expression, yet double antibody blockades of IL-21R and IL-10R did not reveal a

synergistic effect in regulating Th2 or Blimp-1 expression. IL-21 clearly plays a critical

role in supporting Th2 cells in HDM induced allergic lung disease but its mechanism is

independent of Blimp-1 (Coquet et al., 2015). There may be other combinatorial effects

of STAT3 activating cytokines that support Blimp-1 expression, which requires further

study.

Our studies on IL-10 blockade highlights the potentially critical contribution of IL-

10/IL-10R signaling in promoting Th2 cell differentiation in response to allergens. IL-10

is classically thought of as an anti-inflammatory cytokine(Moore et al., 2001). Therefore,

the role of IL-10 in promoting Blimp-1 expression in Th2 cells and subsequent Th2 cell

development may seem at first counterintuitive. One recent study analyzed the

responses of IL-10Rα$^{-/-}$ CD4+ T cells during HDM-induced allergic lung inflammation

and found that IL-10 acts directly on T cells to suppress Th2 cells(Coomes et al., 2016).

In contrast, we found that antibody blockade of IL-10R results in reduced Th2 cells and

a significant loss of Blimp-1 expression within the Th2 compartment. There are several

reports suggesting a STAT6- and IL-4-independent mechanism exists to drive Th2

cells(Dent et al., 1998; Ouyang et al., 2000). Furthermore, IL-10 from IRF4^{+} DCs, the

main Th2-driving DC population, has been implicated in supporting Th2 cells during

allergic responses(Cook and MacDonald, 2016; Gao et al., 2013; Krishnaswamy et al.,

2017; Kumamoto et al., 2013; Williams et al., 2013).Given that many cells can secrete

IL-10, it will be interesting to determine the pertinent cell types involved in this

process(Gabrysova et al., 2014). We postulate that dendritic cells can secrete IL-10

after sensing allergens such as HDM, and then promote Blimp-1 expression and

subsequent Th2 cell development through STAT3 activation. IL-10 can also act in a

paracrine or autocrine manner from T cells to further drive Blimp-1 expression and IL-10

expression, which may further support Th2 cells. However, it is likely additional factors

may act in concert with IL-10 to support Blimp-1, such as TSLP, which can directly limit

Bcl6 via STAT5(Rochman et al., 2018).

Blimp-1 mainly acts as a transcriptional repressor by recruiting histone

methyltransferases such as G9a which results in downregulation of gene

expression(Gyory et al., 2004). Recent studies have identified Blimp-1 binding near the

IL-10 gene, suggesting Blimp-1 may also have a role as an activator of gene

expression(Minnich et al., 2016). However, our study is more in line with an indirect

mechanism of activation whereby Blimp-1 represses Bcl6 which represses IL-

10(Hollister et al., 2013; Xie et al., 2017). Loss of Bcl6 and Blimp-1 together restored IL-

10 expression in T cells, and blockade of IL-10R signaling resulted in robust IL-10$^+$

Blimp-1$^-$ populations, suggesting T cells can make IL-10 in the absence of Blimp-1. We

postulate that there may be more than one way for Blimp-1 to control gene expression

of IL-10, however our studies clearly point to a more complex mechanism beyond

Blimp-1 directly activating the IL-10 gene, at least in CD4 effector cells responding to

allergens in the lung. More studies carefully exploring Blimp-1 and IL-10 expression in T

cells are required to fully understand this complex interaction.

As Blimp-1 has effects in almost every T cell subset, it was important to

determine the intrinsic function of Blimp-1 in Th2 cells in this system. As Th2-specific

deletion of Blimp-1 is challenging, we opted to use mixed bone marrow chimeras, which

supported an intrinsic role for Blimp-1. Mechanistically this was due to the critical

function of Bcl6 in limiting GATA3 expression. Although its known that Bcl6 is an

important repressor of GATA3(Kusam et al., 2003; Sawant et al., 2012), it has not been

appreciated that Blimp-1 plays an important role in suppressing Bcl6 in Th2 cells.

Although STAT5 can also directly suppress Bcl6, our data suggest that this may be

insufficient in some contexts, and that STAT3 driven Blimp-1 is also required to limit

Bcl6 and indirectly support GATA3 and subsequent Th2 cell differentiation(Johnston et

al., 2012; Oestreich et al., 2012). Further studies that explore the complex interplay of

STAT3 and STAT5 activating cytokines in the control of Blimp-1, Bcl6 and GATA3 in

Th2 cells may reveal exactly how Th2 cells differentiate in response to allergens, which

has long been not fully understood.

In summary, our study exploring the T cell intrinsic role of Blimp-1 in HDM

induced allergic airway inflammation has uncovered several findings relevant to the

differentiation of Th2 cells in allergen induced lung inflammation. We found an important

role of STAT3 in promoting Blimp-1 expression and subsequent Th2 cell differentiation.

We additionally determined a potential pro-inflammatory role of IL-10 in driving Blimp-1

expression and promoting inflammation of lung via Th2 cells. Finally, we have described

a new role for Blimp-1 in Th2 cell differentiation by repressing Bcl6 and indirectly

supporting GATA3 expression. Taken together, our study elucidates a new context-

dependent role for Blimp-1 in T cells that promotes, rather than constrains, allergen-

induced airway disease.

Materials and Methods

Mice

C57BL/6NJ (005304), B6.Cg-Tg(Prdm1-EYFP)1Mnz/J (008828), Tg(Cd4-cre)1Cwi/BfluJ

(017336), B6.129-$Prdm1^{tm1Clme}$/J (008100), B6.129S(FVB)-$Bcl6^{tm1.1Dent}$/J (023727),

B6.129S7-$Rag1^{tm1Mom}$/J (002216), B6N.129-Il21r^{tm1Kopf}/J (019115), B6;SJL-$Il6ra^{tm1.Drew}$/J

(012944) were purchased from Jackson Laboratories, Bar Harbor, Maine. STAT3^{flox}

were from D. Levy (MGI: 2384272)*(Lee et al., 2002)* Animals were housed in specific

pathogen–free enclosures at the John G. Rangos Sr. Research Center of UPMC

Children's Hospital of Pittsburgh. All experiments were approved by the University of

Pittsburgh Animal Care Committee and the American Veterinary Medical Association.

All mice were over 6 weeks of age and a mixture of male and female mice were used.

All *in vivo* experiments were performed independently two to three times, with at least 4

mice per group.

Chemicals and Reagents

Flow cytometry antibodies were purchased from BDBiosciences, or ThermoFisher

Scientific(eBioscence). Blocking antibodies (IL-21R, IL-10R and IgG control) were

purchased from BioXCell. CD90 Microbeads were from Miltenyi Biotec. DNAseI, and

Collagenase A were purchased from Sigma-Aldrich. qPCR reagents (Trizol, qScript,

qPCR FastMix II) were purchased from Thermo Fisher Scientific or Quanta Biosciences.

IgE Elisa Kit was purchased from Thermo Fisher Scientific.

House dust mite (HDM) model

492 25 µg of LPS-low HDM (Stallergenes-Greer Pharmaceuticals) was resuspended in 25 µl

493 of sterile PBS and given intranasally to mice anesthetized with isoflurane daily for 10

494 days (priming) and re-challenged two times for 2-3 days per re-challenge with periods of

495 3-4 days rest between challenges (Fig S1A).

Bronchoalveolar lavage fluid (BAL)

After the final re-challenge, BAL was isolated from anesthetized mice by infusion and

recovery of approximately 0.9 ml of sterile PBS into the lungs. Total BAL cell numbers

were determined using automated cell counters (Nexcelom Bioscience LLC. USA), and

$4x10^5$ BAL fluid cells were cytospun onto glass slides for staining using Richard-Allan

Scientific™ Three-Step Stain (Thermo Fisher Scientific) following manufacture's

protocol. Neutrophils, eosinophils, monocytes and lymphocytes were determined out of

a total of 300 cells.

Histology

Lungs fixed in Safefix II (Fisher Scientific) were paraffin embedded, sectioned, and

stained for hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) staining. The

pathological changes were visualized under a microscope.

Flow cytometry

Lungs of anesthetized mice were perfused with sterile PBS, removed and digested.

Briefly, the lung tissues were digested in a collagenase-DNase suspension for 45 min at

37 °C, then processed on a gentleMACS dissociator (Miltenyi Biotec, Bergisch

Gladbach, Germany) according to the manufacture's protocol. Single cell suspensions

were obtained by passing the dissociated tissue through a 70µm cell strainer (Fisher

Scientific) and washed with PBS containing 2% FBS and 0.5M EDTA. Red cells lysis

was performed (ACT lysing buffer, Thermo Fisher Scientific) and washed with PBS

containing 2% FBS. The mediastinal draining lymph node was dissociated in 10 ml of

complete RPMI1640 medium and passed through 40um filters. Cells were stimulated for

2.5 hours with phorbol 12-myristate 13-acetate (PMA) (50ng/ml) and ionomycin

(1µg/ml), with the addition of brefeldin A (GolgiPlug, BD) and monensin. Cells were

processed for staining with fluorochrome-labeled antibodies. Cells were resuspended in

Hanks' balanced salt solution and stained for live/dead using LIVE/DEAD Fixable Dead

Cell Stain and cell surface markers (see table S1 for antibodies). Cells were fixed

overnight with Foxp3 / Transcription Factor Staining Buffer Set (Thermo Fisher

Scientific) and stained with intracellular cytokine or transcription factor staining for 45

min. For intracellular Blimp-1 staining, cells from lung or mediastinal draining lymph

node were stimulated with 10 µg/ml anti-CD3/anti-CD28 or 100 µg/ml HDM for 36

hours, respectively, then re-stimulated with PMA and ionomycin, with the addition of

brefeldin A and monensin for 1.5 hours and processed for staining as above. Cells were

collected using a 5 laser BD Fortessa and analyzed with FlowJo.

Bone marrow chimeras

Bone marrow cells were isolated from femurs of mice, and T cells were depleted using

Thy1.1 or Thy1.2 positive selection and a magnetic separation kit (Miltenyi Biotec). Cells

were counted, mixed in a ratio of 50:50, and injected intravenously into $Rag1^{-/-}$-deficient

hosts. $Rag1^{-/-}$-deficient host mice were lethally irradiated at 750 cGy for 10 min,

followed by 4 hours rest, and a subsequent at 750 cGy for 10 min one day prior to

injection with cells. A total of 20×10^6 cells were injected per mouse. Four weeks after

reconstitution, mice were bled to check reconstitution efficiency, and 6 weeks after

reconstitution, they were used for HDM experiment, as described above.

Antibody blockade

Mice were injected intraperitoneally (i.p.) with 100 µl of sterile PBS containing 0.2 mg of

anti-IL-10R MAb (1B1.3A), anti-IL-21R MAb (4A9), or injected both anti-IL-10R and anti-

IL-21R MAbs on day 1, 3, 5, 7, 9, 15, 17, 21 during the HDM immunization as described

above. Control mice were injected with 0.2 mg IgG1 isotype control (TNP6A7) MAb.

ELISA

The total IgE in the serum was assessed by commercial ELISA kit according to the

manufacturer's protocol.

Quantitative polymerase chain reaction

Total RNA was isolated from lung tissue and mediastinal draining lymph node using

TRIzol Reagent (Thermo Fisher Scientific). About 1 µg RNA was converted into cDNA

using qScript cDNA Synthesis Kit (Quanta BioSciences). Quantitative real-time PCR

(qPCR) was performed on with TaqMan probes [mouse IL-2 (Mm00434256_m1),

mouse IL-4 (Mm00445259_m1), mouse IL-6 (Mm0046190_m1), mouse IL-10

(Mm01288386_m1), mouse IL-21 (Mm00517640_m1), mouse IL-27 (Mm00469294_m1)

and mouse β-actin (Mm02619580_g1), Thermo Fisher Scientific] and TaqMan

PerfeCTa® qPCR FastMix® II mix (Quanta BioSciences) and detected by a CFX96

Real-time PCR Detection Machine (Bio-Rad). ΔΔCt was calculated to determine the

relative expression normalized to β-actin.

In vitro T cell polarization

Naïve CD4 T cells were isolated from spleens and lymph nodes by magnetic

enrichment and flow sorting (CD4$^+$ CD25$^-$ CD44^{lo} CD62L$^+$) and activated with plate-

bound anti-CD3 and anti-CD28 (10ug/ml each) for 3 days in complete RPMI

supplemented with: Th1, IL-12(10ng/ml), anti-IL-4(10ug/ml); Th2, IL-4(10ng/ml), anti-

IFNγ(10ug/ml). Cells were stimulated with PMA, ionomycin, and brefeldin A for 2 hours

prior to flow staining as above.

Statistical Analysis

For statistical analysis, unpaired Mann Whitney t test, one-way Anova or Kruskil-Wallis

test was performed using GraphPad Prism (version 8.02, GraphPad), unless otherwise

specified to calculate statistical significance (reported as means ± SD). A p value of

0.05 was considered significant.

Supplemental material

Fig. S1 shows HDM-induced allergic airway model, in vitro differentiation assays, and

mLN data related to Fig 1. Fig S2 shows Bcl6 expression levels in mLN T$_{FH}$ and Th2

cells. Fig S3 shows T cell subsets and Blimp-1 expression over time in HDM-induced

allergic airway inflammation, and bone marrow chimera experimental setup and

chimerism results. Fig S4 shows mLN data from IL-21R deficient mice related to Fig 6.

Fig S5 shows total IL-10 expression levels after blockade and double blockade

experiments related to Figure 7.

Author Contributions:

Conceptualization, K.H., A.R. and A.C.P; Methodology, S.K., A.R., K.H., and A.C.P;

Investigation and Validation, K.H.,A.H., S.K., and A.C.P; Formal Analysis, K.H., A.H.,

S.K., and A.C.P; Resources, M.M.X., A.L.D., and A.R.; Writing - Original Draft, K.H.,

and A.C.P; Writing – Review & Editing; K.H., A.R. and A.C.P.; Supervision, A.R. and

A.C.P., Funding Acquisition, A.C.P.

Acknowledgments:

We gratefully thank T. Oriss, R. Huff, E. Schmitz, S. Pandya, K. Scholl, H. Yun, J. Chen,

and J. Woodall for technical help with lung isolation, preparation for histology and BAL

counting. We also thank J. Alcorn and M. Manni for expertise, discussions, and use of

cytospin and microscope, and C. Byersdorfer and A. Dobbs for help and expertise with

chimera studies. We also thank M. Mulkeen and the Rangos Histology Core for

histology support, the Division of Laboratory Animal Resources (DLAR) for support

related to animal husbandry, J. Michael and the Rangos Flow Cytometry Core, and the

Unified Flow Core at the University of Pittsburgh for flow cytometry support. We also

thank T. Hand, S. Canna, and M. McGeachy for helpful discussions and comments on

the manuscript. This work benefitted from the BDFortessa funded by NIH grant

1S10OD011925-01. This work was supported by an American Lung Association

Biomedical Research Grant (A.C.P.), and grants from the National Institutes of Health:

AI132771 (A.L.D.), AI106684 and HL113956 (A.R.), and AI135027(A.C.P).

References:

Bao, K., and R.L. Reinhardt. 2015. The differential expression of IL-4 and IL-13 and its impact on
604   type-2 immunity. *Cytokine* 75:25-37.
605   Calderón, M.A., A. Linneberg, J. Kleine-Tebbe, F. De Blay, D.H.F. de Rojas, J.C. Virchow, and P.
606   Demoly. 2015. Respiratory allergy caused by house dust mites: what do we really know?
607   *Journal of Allergy and Clinical Immunology* 136:38-48.
608   Cimmino, L., G.A. Martins, J. Liao, E. Magnusdottir, G. Grunig, R.K. Perez, and K.L. Calame. 2008.
609   Blimp-1 attenuates Th1 differentiation by repression of ifng, tbx21, and bcl6 gene
610   expression. *J Immunol* 181:2338-2347.
611   Cook, P.C., and A.S. MacDonald. 2016. Dendritic cells in lung immunopathology. *Semin
612   Immunopathol* 38:449-460.
613   Coomes, S.M., Y. Kannan, V.S. Pelly, L.J. Entwistle, R. Guidi, J. Perez-Lloret, N. Nikolov, W.
614   Muller, and M.S. Wilson. 2016. CD4+ Th2 cells are directly regulated by IL-10 during
615   allergic airway inflammation. *Mucosal Immunol*
616   Coquet, J.M., M.J. Schuijs, M.J. Smyth, K. Deswarte, R. Beyaert, H. Braun, L. Boon, G.B. Karlsson
617   Hedestam, S.L. Nutt, H. Hammad, and B.N. Lambrecht. 2015. Interleukin-21-Producing
618   CD4(+) T Cells Promote Type 2 Immunity to House Dust Mites. *Immunity* 43:318-330.
619   Cretney, E., A. Xin, W. Shi, M. Minnich, F. Masson, M. Miasari, G.T. Belz, G.K. Smyth, M.
620   Busslinger, S.L. Nutt, and A. Kallies. 2011. The transcription factors Blimp-1 and IRF4
621   jointly control the differentiation and function of effector regulatory T cells. *Nat
622   Immunol* 12:304-311.
623   Croft, M., and S.L. Swain. 1995. Recently activated naive CD4 T cells can help resting B cells, and
624   can produce sufficient autocrine IL-4 to drive differentiation to secretion of T helper 2-
625   type cytokines. *J Immunol* 154:4269-4282.
626   Crotty, S. 2011. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol* 29:621-663.
627   Crotty, S., R.J. Johnston, and S.P. Schoenberger. 2010. Effectors and memories: Bcl-6 and Blimp-
628   1 in T and B lymphocyte differentiation. *Nat Immunol* 11:114-120.
629   D'Cruz, L.M., and L. Klein. 2005. Development and function of agonist-induced CD25+Foxp3+
630   regulatory T cells in the absence of interleukin 2 signaling. *Nat Immunol* 6:1152-1159.
631   Dent, A.L., J. Hu-Li, W.E. Paul, and L.M. Staudt. 1998. T helper type 2 inflammatory disease in
632   the absence of interleukin 4 and transcription factor STAT6. *Proc Natl Acad Sci U S A*
633   95:13823-13828.

Doganci, A., K. Sauer, R. Karwot, and S. Finotto. 2005. Pathological role of IL-6 in the
experimental allergic bronchial asthma in mice. *Clin Rev Allergy Immunol* 28:257-270.

Erle, D.J., and D. Sheppard. 2014. The cell biology of asthma. *J Cell Biol* 205:621-631.

Fontenot, J.D., J.P. Rasmussen, M.A. Gavin, and A.Y. Rudensky. 2005. A function for interleukin
2 in Foxp3-expressing regulatory T cells. *Nat Immunol* 6:1142-1151.

Fu, S.-H., L.-T. Yeh, C.-C. Chu, B.L.-J. Yen, and H.-K. Sytwu. 2017. New insights into Blimp-1 in T
lymphocytes: a divergent regulator of cell destiny and effector function. *Journal of*
biomedical science 24:49.

Gabrysova, L., A. Howes, M. Saraiva, and A. O'Garra. 2014. The regulation of IL-10 expression.
Curr Top Microbiol Immunol 380:157-190.

Gao, Y., S.A. Nish, R. Jiang, L. Hou, P. Licona-Limon, J.S. Weinstein, H. Zhao, and R. Medzhitov.
2013. Control of T helper 2 responses by transcription factor IRF4-dependent dendritic
cells. *Immunity* 39:722-732.

Gyory, I., J. Wu, G. Fejer, E. Seto, and K.L. Wright. 2004. PRDI-BF1 recruits the histone H3
methyltransferase G9a in transcriptional silencing. *Nat Immunol* 5:299-308.

Hollister, K., S. Kusam, H. Wu, N. Clegg, A. Mondal, D.V. Sawant, and A.L. Dent. 2013. Insights
into the role of Bcl6 in follicular Th cells using a new conditional mutant mouse model. *J*
Immunol 191:3705-3711.

Jain, R., Y. Chen, Y. Kanno, B. Joyce-Shaikh, G. Vahedi, K. Hirahara, W.M. Blumenschein, S.
Sukumar, C.J. Haines, S. Sadekova, T.K. McClanahan, M.J. McGeachy, J.J. O'Shea, and D.J.
Cua. 2016. Interleukin-23-Induced Transcription Factor Blimp-1 Promotes Pathogenicity
of T Helper 17 Cells. *Immunity* 44:131-142.

Johnston, R.J., Y.S. Choi, J.A. Diamond, J.A. Yang, and S. Crotty. 2012. STAT5 is a potent negative
regulator of TFH cell differentiation. *J Exp Med* 209:243-250.

Johnston, R.J., A.C. Poholek, D. DiToro, I. Yusuf, D. Eto, B. Barnett, A.L. Dent, J. Craft, and S.
Crotty. 2009. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular
helper cell differentiation. *Science* 325:1006-1010.

Kallies, A., E.D. Hawkins, G.T. Belz, D. Metcalf, M. Hommel, L.M. Corcoran, P.D. Hodgkin, and
S.L. Nutt. 2006. Transcriptional repressor Blimp-1 is essential for T cell homeostasis and
self-tolerance. *Nat Immunol* 7:466-474.

Kallies, A., A. Xin, G.T. Belz, and S.L. Nutt. 2009. Blimp-1 transcription factor is required for the
differentiation of effector CD8(+) T cells and memory responses. *Immunity* 31:283-295.

Kopf, M., G. Le Gros, M. Bachmann, M.C. Lamers, H. Bluethmann, and G. Kohler. 1993.
Disruption of the murine IL-4 gene blocks Th2 cytokine responses. *Nature* 362:245-248.

Krishnaswamy, J.K., U. Gowthaman, B. Zhang, J. Mattsson, L. Szeponik, D. Liu, R. Wu, T. White,
S. Calabro, L. Xu, M.A. Collet, M. Yurieva, S. Alsen, P. Fogelstrand, A. Walter, W.R. Heath,
S.N. Mueller, U. Yrlid, A. Williams, and S.C. Eisenbarth. 2017. Migratory CD11b(+)
conventional dendritic cells induce T follicular helper cell-dependent antibody
responses. *Sci Immunol* 2:

Kumamoto, Y., M. Linehan, J.S. Weinstein, B.J. Laidlaw, J.E. Craft, and A. Iwasaki. 2013.
CD301b(+) dermal dendritic cells drive T helper 2 cell-mediated immunity. *Immunity*
39:733-743.

Kusam, S., L.M. Toney, H. Sato, and A.L. Dent. 2003. Inhibition of Th2 differentiation and GATA-
3 expression by BCL-6. *J Immunol* 170:2435-2441.

Lambrecht, B.N., and H. Hammad. 2015. The immunology of asthma. *Nat Immunol* 16:45-56.

Lee, C.K., R. Raz, R. Gimeno, R. Gertner, B. Wistinghausen, K. Takeshita, R.A. DePinho, and D.E.
Levy. 2002. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-
dependent differentiation. *Immunity* 17:63-72.

Leonard, W.J., and J.J. O'Shea. 1998. Jaks and STATs: biological implications. *Annu Rev Immunol*
16:293-322.

Licona-Limón, P., L.K. Kim, N.W. Palm, and R.A. Flavell. 2013. T H 2, allergy and group 2 innate
lymphoid cells. *Nature immunology* 14:536.

Malek, T.R., A. Yu, V. Vincek, P. Scibelli, and L. Kong. 2002. CD4 regulatory T cells prevent lethal
autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function
of IL-2. *Immunity* 17:167-178.

Martins, G.A., L. Cimmino, J. Liao, E. Magnusdottir, and K. Calame. 2008. Blimp-1 directly
represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. *J Exp*
Med 205:1959-1965.

Martins, G.A., L. Cimmino, M. Shapiro-Shelef, M. Szabolcs, A. Herron, E. Magnusdottir, and K.
Calame. 2006. Transcriptional repressor Blimp-1 regulates T cell homeostasis and
function. *Nat Immunol* 7:457-465.

McBrien, C.N., and A. Menzies-Gow. 2017. The Biology of Eosinophils and Their Role in Asthma.
Front Med (Lausanne) 4:93.

Minnich, M., H. Tagoh, P. Bönelt, E. Axelsson, M. Fischer, B. Cebolla, A. Tarakhovsky, S.L. Nutt,
M. Jaritz, and M. Busslinger. 2016. Multifunctional role of the transcription factor Blimp-
1 in coordinating plasma cell differentiation. *Nature immunology* 17:331.

Moore, K.W., R. de Waal Malefyt, R.L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the
interleukin-10 receptor. *Annu Rev Immunol* 19:683-765.

Neumann, C., F. Heinrich, K. Neumann, V. Junghans, M.F. Mashreghi, J. Ahlers, M. Janke, C.
Rudolph, N. Mockel-Tenbrinck, A.A. Kuhl, M.M. Heimesaat, C. Esser, S.H. Im, A.
Radbruch, S. Rutz, and A. Scheffold. 2014. Role of Blimp-1 in programing Th effector
cells into IL-10 producers. *J Exp Med* 211:1807-1819.

Nurieva, R.I., Y. Chung, G.J. Martinez, X.O. Yang, S. Tanaka, T.D. Matskevitch, Y.H. Wang, and C.
Dong. 2009. Bcl6 mediates the development of T follicular helper cells. *Science*
325:1001-1005.

Oestreich, K.J., S.E. Mohn, and A.S. Weinmann. 2012. Molecular mechanisms that control the
expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene
profile. *Nat Immunol* 13:405-411.

Oliphant, C.J., J.L. Barlow, and A.N. McKenzie. 2011. Insights into the initiation of type 2
immune responses. *Immunology* 134:378-385.

Ouyang, W., M. Lohning, Z. Gao, M. Assenmacher, S. Ranganath, A. Radbruch, and K.M.
Murphy. 2000. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2
development and commitment. *Immunity* 12:27-37.

Ozaki, K., R. Spolski, R. Ettinger, H.P. Kim, G. Wang, C.F. Qi, P. Hwu, D.J. Shaffer, S. Akilesh, D.C.
Roopenian, H.C. Morse, 3rd, P.E. Lipsky, and W.J. Leonard. 2004. Regulation of B cell
differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6.
J Immunol 173:5361-5371.

Parish, I.A., H.D. Marshall, M.M. Staron, P.A. Lang, A. Brustle, J.H. Chen, W. Cui, Y.C. Tsui, C.
Perry, B.J. Laidlaw, P.S. Ohashi, C.T. Weaver, and S.M. Kaech. 2014. Chronic viral
infection promotes sustained Th1-derived immunoregulatory IL-10 via BLIMP-1. *J Clin*
Invest 124:3455-3468.
Pascual, R.M., and S.P. Peters. 2005. Airway remodeling contributes to the progressive loss of
lung function in asthma: an overview. *Journal of Allergy and Clinical Immunology*
116:477-486.
Poholek, A.C., D. Jankovic, A.V. Villarino, F. Petermann, A. Hettinga, D.S. Shouval, S.B. Snapper,
S.M. Kaech, S.R. Brooks, G. Vahedi, A. Sher, Y. Kanno, and J.J. O'Shea. 2016. IL-10
induces a STAT3-dependent autoregulatory loop in Th2 cells that promotes Blimp-1-
restriction of cell expansion via anatagonism of STAT5 target genes. *Science Immunology*
Nov 11:
Pulendran, B., H. Tang, and S. Manicassamy. 2010. Programming dendritic cells to induce T(H)2
and tolerogenic responses. *Nat Immunol* 11:647-655.
Ray, A., and L. Cohn. 1999. Th2 cells and GATA-3 in asthma: new insights into the regulation of
airway inflammation. *J Clin Invest* 104:985-993.
Rincon, M., J. Anguita, T. Nakamura, E. Fikrig, and R.A. Flavell. 1997. Interleukin (IL)-6 directs
the differentiation of IL-4-producing CD4+ T cells. *J Exp Med* 185:461-469.
Rochman, Y., K. Dienger-Stambaugh, P.K. Richgels, I.P. Lewkowich, A.V. Kartashov, A. Barski,
G.K. Khurana Hershey, W.J. Leonard, and H. Singh. 2018. TSLP signaling in CD4(+) T cells
programs a pathogenic T helper 2 cell state. *Sci Signal* 11:
Rutishauser, R.L., G.A. Martins, S. Kalachikov, A. Chandele, I.A. Parish, E. Meffre, J. Jacob, K.
Calame, and S.M. Kaech. 2009. Transcriptional repressor Blimp-1 promotes CD8(+) T cell
terminal differentiation and represses the acquisition of central memory T cell
properties. *Immunity* 31:296-308.
Sawant, D.V., S. Sehra, E.T. Nguyen, R. Jadhav, K. Englert, R. Shinnakasu, G. Hangoc, H.E.
Broxmeyer, T. Nakayama, N.B. Perumal, M.H. Kaplan, and A.L. Dent. 2012. Bcl6 controls
the Th2 inflammatory activity of regulatory T cells by repressing Gata3 function. *J*
Immunol 189:4759-4769.
Seder, R.A., W.E. Paul, A.M. Dvorak, S.J. Sharkis, A. Kagey-Sobotka, Y. Niv, F.D. Finkelman, S.A.
Barbieri, S.J. Galli, and M. Plaut. 1991. Mouse splenic and bone marrow cell populations
that express high-affinity Fc epsilon receptors and produce interleukin 4 are highly
enriched in basophils. *Proc Natl Acad Sci U S A* 88:2835-2839.
Shin, H., S.D. Blackburn, A.M. Intlekofer, C. Kao, J.M. Angelosanto, S.L. Reiner, and E.J. Wherry.
2009. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during
chronic viral infection. *Immunity* 31:309-320.
Stritesky, G.L., R. Muthukrishnan, S. Sehra, R. Goswami, D. Pham, J. Travers, E.T. Nguyen, D.E.
Levy, and M.H. Kaplan. 2011. The transcription factor STAT3 is required for T helper 2
cell development. *Immunity* 34:39-49.
Thomas, W.R. 2016. House Dust Mite Allergens: New Discoveries and Relevance to the Allergic
Patient. *Curr Allergy Asthma Rep* 16:69.
Tournoy, K.G., J.C. Kips, and R.A. Pauwels. 2000. Endogenous interleukin-10 suppresses
allergen-induced airway inflammation and nonspecific airway responsiveness. *Clin Exp*
Allergy 30:775-783.

Turner, C.A., Jr., D.H. Mack, and M.M. Davis. 1994. Blimp-1, a novel zinc finger-containing
protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting
cells. *Cell* 77:297-306.
Webster, K.E., S. Walters, R.E. Kohler, T. Mrkvan, O. Boyman, C.D. Surh, S.T. Grey, and J. Sprent.
2009. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance
to EAE and long-term acceptance of islet allografts without immunosuppression. *J Exp*
Med 206:751-760.
Williams, J.W., M.Y. Tjota, B.S. Clay, B. Vander Lugt, H.S. Bandukwala, C.L. Hrusch, D.C. Decker,
K.M. Blaine, B.R. Fixsen, H. Singh, R. Sciammas, and A.I. Sperling. 2013. Transcription
factor IRF4 drives dendritic cells to promote Th2 differentiation. *Nat Commun* 4:2990.
Xie, M.M., B.H. Koh, K. Hollister, H. Wu, J. Sun, M.H. Kaplan, and A.L. Dent. 2017. Bcl6 promotes
follicular helper T-cell differentiation and PD-1 expression in a Blimp1-independent
manner in mice. *Eur J Immunol* 47:1136-1141.
Xin, A., F. Masson, Y. Liao, S. Preston, T. Guan, R. Gloury, M. Olshansky, J.X. Lin, P. Li, T.P. Speed,
G.K. Smyth, M. Ernst, W.J. Leonard, M. Pellegrini, S.M. Kaech, S.L. Nutt, W. Shi, G.T. Belz,
and A. Kallies. 2016. A molecular threshold for effector CD8(+) T cell differentiation
controlled by transcription factors Blimp-1 and T-bet. *Nat Immunol* 17:422-432.
Yoshimoto, T., A. Bendelac, C. Watson, J. Hu-Li, and W.E. Paul. 1995. Role of NK1.1+ T cells in a
TH2 response and in immunoglobulin E production. *Science* 270:1845-1847.
Zhang, D.H., L. Cohn, P. Ray, K. Bottomly, and A. Ray. 1997. Transcription factor GATA-3 is
differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression
of the interleukin-5 gene. *J Biol Chem* 272:21597-21603.
Zhang, D.H., L. Yang, L. Cohn, L. Parkyn, R. Homer, P. Ray, and A. Ray. 1999. Inhibition of allergic
inflammation in a murine model of asthma by expression of a dominant-negative
mutant of GATA-3. *Immunity* 11:473-482.
Zheng, W., and R.A. Flavell. 1997. The transcription factor GATA-3 is necessary and sufficient for
Th2 cytokine gene expression in CD4 T cells. *Cell* 89:587-596.
Zhou, L., Ivanov, II, R. Spolski, R. Min, K. Shenderov, T. Egawa, D.E. Levy, W.J. Leonard, and D.R.
Littman. 2007. IL-6 programs T(H)-17 cell differentiation by promoting sequential
engagement of the IL-21 and IL-23 pathways. *Nat Immunol* 8:967-974.
Zhu, J. 2015. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2)
development and regulation of interleukin-4 (IL-4) and IL-13 production. *Cytokine* 75:14-
24.
798

Abbreviations:

BAL: bronchiolar lavage fluid

BM: bone marrow

HDM: house dust mite

T_{FH}: T follicular helper

YFP: yellow fluorescent protein

Figure Legends:

<u>Figure 1: T cell expression of Blimp-1 promotes allergic lung inflammation</u>

Analysis of lung tissue isolated from control (Blimp-1$^{f/f}$ CD4Cre$^-$) or Blimp-1^{CD4Cre} (Blimp-

1$^{f/f}$ CD4Cre$^+$) animals i.n. immunized with HDM. A) PAS staining B) Percent and

absolute number of infiltrating inflammatory cells in the BAL. C,E) Flow analysis and

D,F) Percent of indicated subsets of T cells isolated from lungs gated on Live, CD4$^+$

TCRβ$^+$. Data are pooled from 2-3 experiments with 8-13 total mice per group, mean ±

SD. Kruskal-Wallis One-way ANOVA(D) or Mann-Whitney t-test (B,F) *p<0.05 **p<0.01

***p<0.001 ****p<0.0001

<u>Figure 2: IgE responses are Blimp-1 independent</u>

A) Total IgE in serum from animals in Figure 1. B-D) Flow analysis and C-E) Percent of

IL-4, IFNγ and GATA3 expression in mLN T cells gated on Live CD4$^+$ TCRβ$^+$ FoxP3$^-$.

P+I: PMA, ionomycin. F) Flow analysis of IL-4$^+$ cells shown in B. Gated on Live, CD4$^+$

TCRβ$^+$ FoxP3$^-$ IL-4$^+$. Data are pooled from 2-3 experiments with 9-13 total mice per

group, mean ± SD. Mann-Whitney t-test. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

<u>Figure 3: Blimp-1 is intrinsically required in T cells to promote Th2 cells</u>

A) Expression and B) Fold changes of Blimp-1 YFP$^+$ cells in T cell subsets gated on

Live, CD4$^+$ TCRβ$^+$ FoxP3$^-$ in lungs of naïve unimmunized mice or after HDM. Fold

change calculated as percent of Blimp YFP+ in each subset after HDM over average of

Blimp YFP+ in each subset in unimmunized naïve animals C) Flow analysis and D)

Percentages of T cell subsets, IL-10 and Bcl6 expression isolated from lungs of mixed

BM chimeras gated on Live CD4$^+$ TCRβ^+ (Tregs) and FoxP3$^-$ (Th2) and Thy1.1

(Control); or Thy1.2 (Blimp-1^{CD4Cre}) after HDM. E) Eosinophil percentages in BAL of

Control BM chimeras (Control only or Blimp-1^{CD4Cre} only) or mixed BM chimeras. Data

are pooled from 2 experiments with 14 mixed BM chimeras and 1-3 control only BM

chimera mice per group, mean $\pm$ SD. Wilcoxon matched-pairs signed rank test (D)

Mann-Whitney t-test (E). *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

<u>Figure 4: STAT3 is required for Blimp-1 expression in T cells</u>

Analysis of lung tissue isolated from control (STAT3$^{f/f}$ CD4Cre$^-$) or STAT3^{CD4Cre}

(STAT3$^{f/f}$ CD4Cre$^+$) animals i.n. immunized with HDM. A) PAS staining B) Percent of

eosinophils in the BAL. C) Percent of T cell subsets in lung gated on Live, CD4$^+$TCRβ^+.

D) Percent of Blimp-1$^+$ effector T cells (CD4$^+$TCRβ^+FoxP3$^-$CD44$^+$) in mLN and

representative histogram. Data are pooled from 2 experiments with 8 mice total per

group, mean $\pm$ SD. E) Percent of Th1 (IFNγ^+, T-bet$^+$) and Th2 (IL-13$^+$ GATA3$^+$) cells

gated on CD4$^+$TCRβ^+FoxP3$^-$, and F) Blimp-1 YFP+ cells within Th1 and Th2 cells in the

lung after HDM. Data are pooled from 2 experiments with 6-8 total mice per group,

mean $\pm$ SD. Mann-Whitney t-test. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

<u>Figure 5: IL-6 signaling in T cells is not required for Th2 cells in the lung.</u>

Analysis of lung tissue isolated from control (IL-6Rαa$^{f/f}$ CD4Cre$^-$) or IL6Rα^{CD4Cre} (IL-

6R$\alpha^{f/f}$ CD4Cre$^+$) animals i.n. immunized with HDM. A) Percent of indicated subsets of T

cells isolated from lungs gated on Live, CD4$^+$ TCRβ$^+$ FoxP3$^-$ (non-Treg) or FoxP3$^+$

(Treg). B) Percent of Blimp-1$^+$ cells gated on Live, CD4$^+$ TCRβ$^+$ FoxP3$^-$ CD44$^+$. Data

are pooled from 2 experiments with 10 total mice per group, mean ± SD. Mann-Whitney

t-test. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001 C) qPCR of indicated cytokines in

lungs and mLN of unimmunized or HDM-immunized animals.

<u>Figure 6: IL-21 is not required for Blimp-1 mediated Th2 cell differentiation</u>

Analysis of lungs isolated from IL-21R-intact or IL-21R-deficient animals (A-C), or

control (IgG) or anti-IL-21R treated animals (D-E) i.n. immunized with HDM. A) Percent

of eosinophils in the BAL. B) Percent of Th1 (IFNγ$^+$, T-bet$^+$) and Th2 (IL-13$^+$ GATA3$^+$)

cells in lung gated on Live, CD4$^+$TCRβ$^+$FoxP3$^-$. C) Expression of Blimp-1 and Bcl6 in

lungs in T cells gated on Live, CD4$^+$TCRβ$^+$FoxP3$^-$. Data are pooled from 3 experiments

with 9-10 mice total per group, mean ± SD, Mann-Whitney t-test. D) Percent of Th1

(IFNγ$^+$, T-bet$^+$) and Th2 (IL-13$^+$ GATA3$^+$) cells in lung gated on Live, CD4$^+$TCRβ$^+$FoxP3$^-$

and E) Blimp-1 YFP$^+$ cells within Th1 and Th2 cells in the lung after HDM. Data are

pooled from 2 experiments with 6-7 mice total per group, mean ± SD, Mann-Whitney t-

test. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

<u>Figure 7: IL-10 is required for Blimp-1 expression in Th2 cells</u>

Analysis of lungs isolated control (IgG) or anti-IL10R treated animals i.n. immunized

with HDM. A) Percent of eosinophils in the BAL. B) Flow analysis of Th1 and Th2 cells

in lung. C) Percent of Th1 and Th2 cells in lungs gated on Live, CD4$^+$TCRβ$^+$FoxP3$^-$. D)

Flow analysis and E) Percent of Blimp-1 YFP$^+$ cells in Th1 and Th2 cells in the lungs. F)

Flow analysis and G) Percent of IL-10$^+$ and Blimp-1 YFP$^+$ expression in Th1 and Th2

cells in lungs. Data are pooled from 3 experiments with 11-12 mice total per group,

mean$\pm$ SD. Mann-Whitney t-test. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

<u>Figure 8: Transcription factor expression in effector T cells in the absence of Blimp-1.</u>

A) Percent of effector cells expressing the transcription factors shown isolated from lung

after HDM. Gated on Live, CD4$^+$ TCRβ^+ FoxP3$^-$ CD44$^+$. B) Histograms of data from A

comparing naïve, Control effector (CD44$^+$) or Blimp-1^{CD4Cre} effector (CD44$^+$) T cells.

Data are pooled from 2-3 experiments with 8-10 total mice per group. Mann Whitney t-

test. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

<u>Figure 9: Blimp-1 supports Th2 development through suppression of Bcl6</u>

Analysis of lungs isolated from Control, Bcl6^{CD4Cre}(Bcl6$^{f/f}$ CD4Cre$^+$), Blimp-1^{CD4Cre}(Blimp-

1$^{f/f}$ CD4Cre$^+$), or doubleKO^{CD4Cre}(Bcl6$^{f/f}$ Blimp-1$^{f/f}$ CD4Cre$^+$) animals i.n. immunized with

HDM. A) PAS staining B) Percent of eosinophils in the BAL C) Percent of Th1(IFNγ^+, T-

bet$^+$), Th2 (IL-13$^+$ GATA3$^+$) and Treg (FoxP3$^+$) cells isolated from lungs gated on Live,

CD4$^+$TCRβ^+ (Treg), and FoxP3$^-$ (non-Treg). D) Total IgE in serum. E) Percent of IL-10$^+$

cells in effector (CD4$^+$TCRβ^+FoxP3$^-$, left) or Treg (CD4$^+$TCRβ^+FoxP3$^+$, right) cells in

lung. Data are pooled from 3 experiments with 7-17 total mice per group, mean$\pm$ SD.

Kruskal-Wallis One-way ANOVA. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

<u>Figure S1: *In vitro* T cell differentiation, and T cell subsets in mLN after HDM</u>

A) Schematic for HDM-induced allergic lung inflammation model used throughout this

study. B) Flow staining of Th1 (IFNγ$^+$, T-bet$^+$) and Th2 (IL-13$^+$ GATA3$^+$) in vitro

polarization of T cells isolated from Control or Blimp-1^{CD4Cre} animals. C) Percent of

indicated subsets of T cells isolated from mLN gated on Live, CD4$^+$ TCRβ$^+$. Data are

pooled from 2-3 experiments with 8-13 total mice per group, mean ± SD. Mann-Whitney

t-test *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

Figure S2: Bcl6 expression in T$_{FH}$ and Th2 cells in the mLN.

A) Expression of Bcl6 in indicated populations. Geometric Mean shown in top right

corner of each track. B) Geometric Mean of Bcl6 in indicated samples. Wilcoxon

matched-pairs signed rank test. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

Figure S3: Blimp-1 YFP expression over time and BM chimera reconstitution.

A) Absolute number of CD4 T cell subsets during the course of HDM-induced allergic

lung inflammation model. B) Absolute number of Blimp-1 YFP$^+$ cells of each CD4 T cell

subset shown in A. C) Flow analysis and Fold change of Blimp-1 YFP$^+$ FoxP3$^+$ Treg

cells in the lung of naïve unimmunized animals and after HDM. Fold change calculated

as percent of Blimp-1 YFP$^+$ Tregs after HDM over average of Blimp-1 YFP$^+$ Treg cells in

unimmunized mice. D) Schematic of mixed bone marrow chimera generation E)

Reconstitution 4-6 weeks post irradiation and injection of donor marrow isolated from

blood (4 weeks) or lungs post HDM-induced lung inflammation. Flow cytometry and

percent of Thy1.1$^+$ (Control) and Thy1.2$^+$ (Blimp-1^{CD4Cre}) in both tissues shown.

Wilcoxon matched-pairs signed rank test. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

<u>Figure S4: IL-21R signaling is required for T cell responses but not Blimp-1 in the mLN.</u>

A) Percent of Th1 (IFNγ^+, T-bet$^+$) and Th2 (IL-13$^+$ GATA3$^+$) cells in mLN gated on Live,

CD4$^+$TCRβ^+FoxP3$^-$. B) Expression of Blimp-1 and Bcl6 in mLN in T cells gated on Live,

CD4$^+$TCRβ^+FoxP3$^-$. Data are pooled from 3 experiments with 9-10 mice total per group,

mean $\pm$ SD, Mann-Whitney t-test. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

<u>Figure S5: IL-10 and IL-21 do not cooporatively regulate Blimp-1 expression.</u>

A) Percent of IL-10 expressing cells isolated from the lung gated on Live, CD4$^+$ TCRβ^+

FoxP3$^-$ CD44$^+$. B) Percent of Th1 (IFNγ^+, T-bet$^+$) and Th2 (IL-13$^+$ GATA3$^+$) cells in the

lung isolated from Blimp-1 YFP animals treated as Control (IgG) or treated with anti-IL-

10R, anti-IL21R, or both anti-IL-10R and anti-IL21R for the duration of the HDM-induced

allergic lung inflammation model. C) Percent of Blimp-1 YFP$^+$ Th1 and Th2 cells in B.

Data are pooled from 2-3 experiments with 6-10 total mice per group. Kruskal-Wallis

One-way ANOVA. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001

Figure 1: Blimp-1 in T cells promotes allergic airway inflammation

Figure 2: IgE responses are Blimp-1 independent

Figure 3: Blimp-1 is intrinsically required in T cells to promote Th2 cells

Figure 4: STAT3 is required for Blimp-1 expression in T cells

Figure 5: IL-6 signaling in T cells is not required for Th2 cells in the lung.

Figure 6: IL-21 is not required for expression of Blimp-1 in Th2 cells

Figure 7: IL-10 is required for Blimp-1 expression in Th2 cells

Figure 8:Transcription factor expression in effector T cells in the absence of Blimp-1

Figure 9: Blimp-1 supports Th2 development through suppression of Bcl6

Figure S1: In vitro T cell differentiation and T cell subsets in mLN after HDM.

A House dust mite induced allergic airway model

B

C

Figure S2: Related to Figure 2. Bcl6 expression in T_{FH} and Th2 cells in the mLN.

A

133	Naive
99	Control GATA3$^+$ IL-4$^+$
345	Control GATA3$^-$ IL-4$^+$
671	Blimp-1^{CD4Cre} GATA3$^+$ IL-4$^+$
633	Blimp-1^{CD4Cre} GATA3$^-$ IL-4$^+$

Bcl6

B

Control

Geo Mean Bcl6

- GATA3$^+$ IL-4$^+$ (Th2)
- GATA3$^-$ IL-4$^+$ (T$_{FH}$)

Figure S4: IL-21R signaling is required for T cell responses but not Blimp-1 in mLN

A

Th1

Th2

● IL21R[+/+]
○ IL21R[-/-]

B

Blimp-1[+]

Bcl6[+]

● IL21R[+/+]
○ IL21R[-/-]

Figure S5: IL-10 and IL-21 do not cooporatively regulate Blimp-1 expression.

A

IL-10$^+$

- IgG
- anti-IL-10R

B

Th1

Th2

- IgG
- anti-IL10R
- anti-IL21R
- anti-IL10R+anti-IL21R

C

Blimp-1 YFP$^+$

Blimp-1 YFP$^+$

- IgG
- anti-IL10R
- anti-IL21R
- anti-IL10R+anti-IL21R